Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study
- First Online:
- Cite this article as:
- Hashmi, J.A., Baliki, M.N., Huang, L. et al. Mol Pain (2012) 8: 29. doi:10.1186/1744-8069-8-29
- 12k Downloads
The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks).
There was no significant difference between the treatment groups in either pain intensity, sensory and affective qualities of pain or in pain related brain activation at any time point. However, 50% patients in both the Lidocaine and placebo arms reported a greater than 50% decrease in pain suggesting a marked placebo effect. When tested against an untreated CBP group at similar time points, the patch treated subjects showed significantly greater decrease in pain compared to the untreated group (n = 15).
These findings suggest that although the 5% Lidocaine is not better than placebo in its effectiveness for treating pain, the patch itself induces a potent placebo effect in a significant proportion of CBP patients.
KeywordsChronic pain fmri Clinical trial Placebo Lidocaine Topical analgesic
Multiple lines of evidence suggest that aberrant activity in sodium channels contributes to chronic pain conditions that involve neuropathy. Blocking sodium channels such as with systemic Lidocaine reduces evoked intensity of acute pain [1, 2, 3, 4, 5] and also relieves pain in some patient populations such as in chronic post herpetic neuralgia [2, 6, 7]. The main mechanism through which Lidocaine is said to act is by inhibition of ectopic discharge in sensitized and hyperactive cutaneous nociceptors. In addition, a central analgesic effect of Lidocaine has also been suggested [5, 8].
The most advocated mode of Lidocaine administration is with 5% Lidocaine adhesive patches that are applied to the affected area and act by local absorption [9, 10]. The systemic absorption is minimal; hence the chances of adverse side effects are low. However, the effectiveness of patches medicated with Lidocaine (5%) in reducing pain is less clearly understood. Some recent studies reported that 5% Lidocaine patches either have variable effects or no effects in acute pain models of pain in healthy subjects suggesting a partial and inconsistent block of nociceptors [11, 12, 13]. These findings raised important questions regarding the mechanisms and potential efficacy of Lidocaine patches in reducing pain and led to the speculation that Lidocaine patches may be more effective in reducing pathological pain related with an abnormally increased expression of sodium channels . This assumption is based on the fact that chronic pain patients with neuropathic pain conditions such as low back pain, painful diabetic neuropathy and complex regional pain syndrome benefit from treatment with topical Lidocaine, but even in these conditions, the effects of Lidocaine on pain are variable between subjects and can range from 29% to 80% of the studied cases [2, 11, 14, 15, 16, 17, 18]. Whether Lidocaine patches are effective in treating chronic back pain is particularly unclear since the purported effectiveness of the treatment is derived from open labelled clinical trials [18, 19, 20, 21]. fMRI studies have also shown central analgesic effects of 5% Lidocaine, but again these studies were not controlled for a placebo effect [18, 20, 22, 23, 24, 25].
It is not known whether the 5% Lidocaine patch has a true pharmacological effect on chronic back pain or if it is a potent placebo. Here we aimed to study how the 5% Lidocaine patch compares with a placebo patch in reducing pain of CBP and to investigate brain activity that can differentiate between the treatments. We hypothesised that pain and related brain activity will diminish more in participants in the active treatment arm. In a randomised double-blind, placebo controlled clinical trial, 30 CBP patients received drug or placebo treatment and underwent brain imaging to identify activity for fluctuations of spontaneous pain, at baseline and at two time points (6 hours and 2 weeks) after start of treatment. Moreover, we investigated inter-individual differences in pain responses to test whether a subset of patients is more responsive to Lidocaine treatment than placebo treatment.
Effects of Lidocaine vs. placebo on CBP pain
The chronic back pain intensity (peak pain in spontaneous pain ratings on numerical 0-100 scale and visual analog 0-10 scale values) and back pain properties (sensory, 0-33 scale, and affective, 0-12 scale, pain qualities from MPQ) were compared between the two treatment groups at baseline, 6 hours, and 2 weeks post treatment using a repeated-measures two-way (drug and placebo treatment arms by sessions) repeated-measures analysis of variance (2-RM-ANOVA). The peak rating of spontaneous pain and the VAS scores were strongly correlated with each other (R = 0.53, p ≪ 0.002, n = 30), and since the spontaneous pain was collected during fMRI acquisition, we designated its peak pain rating as the pain intensity criterion for brain activity. Also note that at baseline, there was no significant difference (p ≫ 0.05) between the two groups in depression scores (BDI), anxiety scores (BAI) or neuropathic pain scores (NPS).
For both Lidocaine and placebo treated groups, there was a decrease in the sensory and affective MPQ scores for treatment duration (Sensory: F2,84 =11.6, p ≪ 0.0001; affective F2,84 = 22.66, p = 0.0001), but there was no treatment type effect at 6 hours (sensory p ≫ 0.5; affective p ≫ 0.3) or at 2 weeks (sensory p ≫ 0.1; affective p ≫ 0.4) (Figure 1B-E). Overall, the effects of Lidocaine patch on CBP pain could not be distinguished from that of placebo. Yet, we observe decreased pain of CBP with continued treatment for both treatment groups. Note that there were no harmful or unintended effects reported by subjects in either group.
Effects of Lidocaine vs. placebo on CBP pain related brain activity
Patient clinical characteristics
Inter individual differences in patch induced analgesia
Next, we compared the change in pain between the Lidocaine and placebo treated groups within the subset of subjects that showed a more than median decrease in pain i.e. the CBP decreasing group. The mean percent change in pain in the Lidocaine treated group (54.7%, SEM = 9.81) was not significantly different (t = 0.25, p = 0.8) from the placebo treated group (59.7% SEM = 10.316). Moreover, pain related brain activity was not significantly different between the placebo and Lidocaine treated subjects within the CBPd subset with a less stringent fixed-effects contrast. Using the same technique, contrasting brain activity between the Lidocaine and placebo treated subjects within the CBPp group showed no significant difference between the two groups.
Is the patch a potent placebo?
The effects of 5% Lidocaine patch were indistinguishable from the placebo patch, but one remaining question was the marked reduction in pain observed in both Lidocaine and placebo treated groups. A greater than 50% reduction in clinical pain in a large proportion of subjects represents a marked effect and this analgesia could have been caused by a number of factors associated with the experiment. For instance, the clinical trial setting, expectation of pain relief from a treatment and the twice daily application of the patch for two weeks may have acted as a potent placebo. Alternatively, the reduction in pain in the CBPd group may have been due to other disease related factors such as due to natural fluctuations in pain intensity. Therefore, we compared back pain between the observational group (CBP observed, n =15) and the treatment group (CBP treatment, n = 30), at baseline and after two weeks. Within this time period, VAS rating for back pain significantly decreased for the CBP treatment but not for the CBP observed group (2-RM-ANOVA for the two groups and visits F 2,43 = 8.33, p = 0.03; post-hoc comparisons show 1. no difference between groups at baseline, p ≫ 0.1, 2. no difference between baseline and 2-weeks for CBP observed group p ≫ 0.6, 3. a significant decrease in VAS pain for CBP treatment group between baseline, 6.6 ± 0.07, and 2-weeks, 3.8 ± 0.09, t58 = 4.3, p ≪ 0.001) (Figure 3A). Note that between the two groups there was no difference in 1) back pain duration (CBP treatment 14.2 ± 0.39 years, in contrast to CBP observed 14.5 ± 0.5, t-test p ≫ 0.9), 2) a borderline difference in age (t-test, p = 0.06), 3) no difference in gender (Mann Whitney rank sum test, p = 0.4), and 4) no difference in depression (t-test, p ≫ 0.4), attesting to the close match between the treatment and observed CBP groups. Therefore, we conclude that the presence of the potential analgesic treatment within the clinical trial setting was critical for the decrease in back pain intensity observed after two weeks in the CBP treatment group.
Here we demonstrate that 5% Lidocaine patch reduces the magnitude of CBP through a mechanism that cannot be distinguished from the effects of the placebo patch. However, pain intensity was reduced in a significant proportion of subjects in the 5% Lidocaine and placebo treated groups. These findings indicate that the therapeutic effectiveness of 5% Lidocaine observed in other back pain studies was due to the potent placebo properties of the patch itself and not due to a pharmacological action of the drug.
Placebo controlled clinical trials have shown that systemic or topical Lidocaine reduces severity of chronic post-herpetic neuropathy, neuropathic pain, and for pain associated with inflammatory bowel disease [4, 26, 27]. This is the first placebo controlled clinical trial for 5% Lidocaine in chronic back pain and our findings indicate that the analgesic effects of 5% Lidocaine patch on CBP could not be distinguished from the placebo patch. In addition, there was a generalized decrease in sensory and affective pain qualities after treatment, but even in these measurements, the 5% Lidocaine treated group was not significantly different from the placebo group. In other clinical conditions such as painful diabetic neuropathy and complex regional pain syndrome, the drug showed greater benefit than placebo, but the effectiveness was variable ranging from 29% to 80% of studied cases [11, 16, 17, 18, 19].
The mode of action of topical Lidocaine is not clear and clearly shows inter individual variability in responsiveness between patients with neuropathic pain syndromes and also in evoked pain responses in healthy subject after treatment. In one study, several patients with complete loss of electric nerve function and marked subepidermal nerve-fiber plexus denervation in the peripheral limb showed a response to the Lidocaine patch . An important implication of this study was that electric nerve function is not an essential for the mechanisms of 5% Lidocaine therapeutic action. Even in healthy subjects, 5% Lidocaine was not more effective than placebo in treating experimental pain and innocuous sensation including heat evoked pain, mechanical pain and capsaicin induced pain [11, 12, 13]. These negative findings led to the speculation that the 5% Lidocaine is too low a dose to effectively block healthy nociceptors, but may block pathological activity associated with upregulated sodium channels that result in neuropathic pain [11, 14]. The Lidocaine patch has been suggested to affect neuropathic pain by a local non selective stabilization of sodium channels on cutaneous afferents at or near the site of application [1, 9]. The findings of the present study corroborated by other studies raise some questions in this regard and show that Lidocaine was not more effective than placebo in treating chronic back pain that does have a significant contribution from neuropathic sources.
The 5% Lidocaine patch is an off label treatment for chronic back pain. This treatment has been increasingly advocated due to its purported effectiveness and is recommended over other treatments due to fewer side effects [19, 28, 29]. The confidence in the efficacy of the 5% Lidocaine patch especially for treating CBP is based mainly on open labelled trials and the role of placebo analgesia in mediating the actions of the 5% Lidocaine patch had not been tested before. Our findings suggest that the 5% Lidocaine patch acts as potent placebo and has no detectable pharmacological effect in either pain report or in brain activity. The fact that a nearly equal number of subjects in the Lidocaine and placebo arm reported a marked decrease in pain indicates that the effects of just the patch itself irrespective of the presence of drug can produce analgesia through endogenous pain regulatory mechanisms associated with placebos [30, 31, 32]. A putative placebo mechanism in reducing pain is reflected by the fact that only the patch treated group as a whole showed a significant reduction in pain intensity when compared to a group of CBP patients that were not given any treatment. This observation explains the positive findings we had reported in a previous report where in an open labelled trial, the 5% Lidocaine patch was effective in reducing pain intensity on average accompanied with related changes in pain related brain activation patterns after treatment . However, in the present and in the preliminary study, we observed a marked reduction in clinical pain after treatment that suggests that the patch induces a potent placebo analgesia.
However, the present study also demonstrates that not all subjects responded with analgesia to the patch, and the percent change in pain was negligible in half of the subjects. Thus, the placebo effect induced by the patches is subject to a prominent inter-individual variability and this extent of variability has not been observed in previous placebo studies [31, 33, 34, 35]. This could be because most placebo studies have studied healthy subjects and placebo responses in clinical populations may be affected by disease chronicity. Another prominent factor is that unlike most placebo studies where a group of subjects is conditioned to believe in the benefits of the treatment [36, 37], here all patch treated subjects were given similar open ended instructions that the treatment may or may not reduce their pain. Thus the psychobiological mechanisms that lead to reduction or no reduction in pain would be reflective of each individuals own expectations, belief in the treatment and anxiety about the treatments potential benefits.
One limitation of this study is that the number of subjects is lower than what would be required for a clinical trial. However, corroborated by other studies, these findings indicate that a large sample size would result in a similar outcome. A calculation for the required sample size to achieve a clinically relevant change in pain of 20 % combined with the present findings required 536 subjects to achieve a desired power of 0.85 (large effect size). Such a large number of chronic back pain subjects would be extremely difficult if not unachievable to recruit for an fMRI study. Nevertheless, additional studies are needed that test the effects of the 5% Lidocaine patch against a placebo to arrive at a solid conclusion regarding the efficacy of this treatment in chronic back pain.
Recently, the 5% Lidocaine patch has emerged as first line therapy and since side effects are lower than oral or systemic doses, its use has become popular especially in geriatric populations. Our findings raise some important considerations since even though the 5% Lidocaine had no direct effect; the patch itself induces analgesia that is two to three folds higher than the accepted clinical level of 20% , but a discussion about the ethics of using placebos that produce strong analgesic effects is beyond the scope of the objectives of this study. This study brings to bear “the elephant in the room” issue relating to the ever present placebo effect in analgesic trials. This study also raises the need for more consideration into whether the clinical use of the Lidocaine patch in CBP is warranted. Overall, based on these findings, we conclude that the 5% Lidocaine patch has no drug mediated action on intensity of CBP; however, it does reduce pain intensity in more than 50% of subjects that is most likely due to a placebo effect. Our findings suggest that the patch is a potent agent for inducing placebo analgesia.
Coordinates of brain regions activated in relation to spontaneous ratings of CBP
co-ordinatesx y z
P - values
CBP baseline activity pain task
(BA 9, 32)
CBP baseline activity
pain task>visual control
(BA 9, 32)
Lidocaine: CBP baseline activity
(BA 9, 32)
Placebo: CBP baseline activity
(BA 9, 32)
Subject groups and experimental sessions for brain imaging with treatment
Efficacy for pain relief by 5% Lidocaine patch was tested in a randomised, double blind, placebo controlled longitudinal study. Of the patients recruited to this part of the study, data from 15 CBP patients that received the patches containing 5% Lidocaine and 15 age and sex matched CBP patients that received a patch containing the vehicle and no Lidocaine (placebo arm) were included in the analysis. Participants were randomly selected to receive drug or placebo. The Northwestern University Clinical Unit personnel generated the random allocation sequence using a random number generator, and held its key to the end of the study. All patients and experimenters (while delivering treatments, scanning and analyzing data) were blinded to type of treatment. The first application of the unlabeled patch was carried out by a clinician (blinded to type of treatment) who also explained the proper use of the patch. The patient was supplied with a measured number of unlabeled patches (identical between drug and placebo arms) and specific instructions were given to self administer the patch twice daily at 12 hour intervals for a period of two weeks. There was no difference in the appearance of the patches that contained Lidocaine or no drug.
Experimental tasks and fMRI data acquisition
Each volunteer in this group participated in three experimental sessions. The first session was conducted immediately before start of treatment (baseline), the second session was performed 6 hours after application of the first set of patches and the third session was after 2 weeks of using the patches. At baseline, the patients filled out questionnaires related to their pain that included the McGill pain questionnaire (MPQ), neuropathic pain scale (NPS), Beck depression inventory (BDI) and Beck anxiety inventory (BAI). Before scanning, participants were trained on a finger-span device that was later used for acquiring continuous ratings of the fluctuations of spontaneous pain of CBP, on a numerical scale ranging from 0-100 during functional scans. This device was composed of a potentiometer the voltage of which was digitized and time-stamped in reference to fMRI image acquisition and connected to a computer providing visual feedback of the ratings [39, 40]. In addition to the pain-rating task, subjects were trained to perform a visual rating task  during which subjects rated the changes in the length of a bar on the 0-100 numerical rating scale projected on a screen. The length of the bar varied over time to match the pain ratings obtained from the subject in the preceding scan. Thus this task serves as a control for task-related activations such as visual inputs, motor performance, magnitude estimation, attention, and anticipation.
After training, the subjects were placed in the scanner, T1-weighted structural images and fMRI data were collected while subjects performed pain or visual rating tasks In addition to the pain rating scan, a visual rating task scan was acquired in which the subject rated the length of the bar as it varied over time in conjunction with the subjects own pain ratings obtained in one of the preceding spontaneous pain rating scans.
fMRI data were acquired with a 3-T Siemens Trio whole body scanner with echo-planar imaging (EPI) capability using the standard radio-frequency head coil. Multislice T2*-weighted echoplanar images were obtained with the following parameters: repetition time (TR) = 2.5 s; echo time (TE) = 30 ms; flip angle = 90°, slice thickness = 3 mm, in-plane resolution = 64 × 64. The 36 slices covered the whole brain from the cerebellum to the vertex. A total of 244 volumes were acquired per condition in all participants and the first 4 volumes were discarded during the preprocessing step. A T1-weighted anatomical MRI image was also acquired for each subject using the following parameters: TR = 2.1 s, TE = 4.38 ms, flip angle = 8°, field of view = 220 mm, slice thickness = 1 mm, in-plane resolution = 0.86 × 0.86 mm2, and number of sagittal slices = 160.
Session 2 (6 hrs) and 3 (2 weeks) procedures were similar to session 1, patients filled out MPQ at all three time points. Some subjects had missing values in sensory and affective scores (n = 3 at 6 hour and n = 2 at 2 weeks) scores in the MPQ and were not included in corresponding statistical testing. This was followed by scanning procedures identical to those used at baseline.
The CBP patients in the observational group received no treatment. They filled out the McGill Pain Questionnaire at baseline and after a two-week period. They too were trained on the finger span device and had fMRI scan at their second visit (not analyzed for the present study). For this group, change in back pain was assessed between baseline and the second visit, using the visual analog scale (VAS) of the MPQ questionnaire.
Image pre-processing and GLM analysis
Image analysis to reveal significant brain activity based on changes in blood oxygen level-dependent (BOLD) signal was performed on each patient’s data using Functional Magnetic Resonance Imaging of the Brain (FMRIB) Expert Analysis Tool [(FEAT; ; http://www.fmrib.ox.ac.uk/fsl)]. The data pre processing were conducted using the FSL 4.1  and MATLAB 7.9. First, the skull of brain was extracted and the first 4 volumes were removed to compensate for scanner drifts. Moreover, typical FSL preprocessing was implemented which includes slice-time correction spatial smoothing with 5mm kernel, intensity normalization, and high-pass filtering (150 sec). The mean BOLD signal from white matter, cerebrospinal fluid, and whole brain without skull and the 6 motion components from motion correction, and motion outlier vectors were regarded as covariates of no interest and regressed out from the BOLD signal. In addition, probabilistic Independent Component Analysis was then implemented in MELODIC (Multivariate Exploratory Linear Decomposition into Independent Components) to select artefact components, using an automated procedure that identified and removed edge components and signal dropout components. The fMRI signal was then linearly modeled on a voxel by voxel basis using FMRIB’s Improved Linear Model (FILM) with local autocorrelation correction [42, 43].
Analysis of effects of Lidocaine vs. placebo
For this step, the experimenter was given a code that separated the subjects into two groups. However, the experimenter was not informed about the type of treatment (5% Lidocaine or placebo). The chronic back pain intensity (peak pain in spontaneous pain ratings on numerical scale and visual analog scale values) and back pain properties (sensory and affective pain qualities) were compared between the two groups at all three scan sessions using a repeated measures analysis of variance.
Brain function in the two groups was assessed for each session for ratings of spontaneous pain and for visual control ratings. Ratings were binarized relative to the mean rating of spontaneous fluctuations of back pain  and convolved with a canonical hemodynamic response function (gamma function: lag, 6 s; SD, 3 s). The significance of the model fit to each voxel time series was calculated, yielding statistical parametric maps for each subject and condition. All group level analyses were carried out using FEAT in a random effects analysis after the co-registration of individual scans to standard space [152 subject average Montreal Neurological Institute (MNI) space, http://www.bic.mni.mcgill.ca/cgi/icbm_view/. Average group activity map was generated for 30 subjects to ascertain the region that corresponds significantly with spontaneous pain ratings. The next averaged map was generated by subtracting the visual activity maps from the pain activity maps with a paired t-test. Subsequently, averaged maps for each group (5% Lidocaine and placebo) were generated for the three time points. Furthermore, brain activation was contrasted between the Lidocaine and placebo group at all three time points using a random effects unpaired t-test analysis. These contrasts result in Z- score maps of statistically significant pain-related activity across different conditions. To correct for multiple comparisons, cluster-based corrections of the Z-statistic images were performed. The raw Z-statistic images from the group analysis were thresholded at Z-scores ≫ 2.3. For each resulting cluster of spatially connected voxels surviving the Z threshold, a cluster probability threshold of p ≪ 0.05 was applied to the computed significance of that cluster, which corrects for multiple comparisons according to Gaussian random field theory . All imaging analyses were corrected for confounds due to age, sex and depression (BDI) scores.
Interindividual differences in treatment response
To investigate inter individual differences in treatment response we selected the 2 week period as the time point of interest and calculated change in pain from baseline. The median change was used to regroup CBP into persistent and decreasing (CBPp and CBPd). The questionnaire data was analyzed to assess differences between the two groups.
We thank Judy L. Paice for help in instructing participants for proper use of therapy. We thank all participants in the study, and Apkarian lab personnel for help in various aspects of the study and insightful discussions. The study was funded by Endo Pharmaceuticals and in part by National Institutes of Health R01 NS35115. Endo Pharmaceuticals provided financial aid, Lidocaine and placebo patches, but had no involvement in other aspects of the project. The registration number for ClinicalTrials.gov is NCT015540 and the registry name is “Brain imaging of Lidoderm for chronic back pain”. The full trial protocol can be accessed at clinicaltrials.gov.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.